Hand-Foot-and-Mouth Disease (HFMD)

Back

Practice Essentials

Hand-foot-and-mouth disease (HFMD) is an acute viral illness that presents as a vesicular eruption in the mouth (see the image below), but it can also involve the hands, feet, buttocks, and/or genitalia. Coxsackievirus A type 16 (CVA16) is the etiologic agent involved in most cases of HFMD, but the illness is also associated with coxsackievirus A5, A7, A9, A10, B2, and B5 strains. Enterovirus 71 (EV-71) has caused outbreaks of HFMD with associated neurologic involvement in the western Pacific region.



View Image

The lower lip has an ulcer with an erythematous halo.

See Clues in the Oral Cavity: Are You Missing the Diagnosis?, a Critical Images slideshow, to help identify the causes of abnormalities of the oral cavity.

Also, see the 15 Rashes You Need to Know: Common Dermatologic Diagnoses slideshow to help identify and treat various rashes and the 15 Back-to-School Illnesses You Should Know slideshow to help identify conditions that may occur in young patients after they return to the classroom.

Signs and symptoms

The history in patients with HFMD is as follows:

Physical findings include the following:

Atypical clinical features include concomitant aseptic meningitis in HFMD caused by coxsackievirus strains (rare).[1] HFMD caused by EV-71 has a higher incidence of neurologic involvement, including the following[2] :

See Clinical Presentation for more detail.

Diagnosis

The diagnosis of HFMD is typically based on clinical grounds. Laboratory studies are usually unnecessary, but the following may be done:

See Workup for more detail.

Management

There is no antiviral agent specific for the etiologic agents of HFMD. Instead, the treatment is supportive, as follows:

See Treatment and Medication for more detail.

Background

Hand-foot-and-mouth disease (HFMD) is an acute viral illness that presents as a vesicular eruption in the mouth. HFMD can also involve the hands, feet, buttocks, and/or genitalia. Coxsackievirus A type 16 (CV A16) is the etiologic agent involved in most cases of HFMD, but the illness is also associated with coxsackievirus A5, A7, A9, A10, B2, and B5 strains. Enterovirus 71 (EV-71) has also caused outbreaks of HFMD with associated neurologic involvement in the western Pacific region.

Coxsackievirus is a subgroup of the enteroviruses and is a member of the family Picornaviridae. This family consists of small, nonenveloped, single-stranded RNA viruses.

Pathophysiology

Infection generally occurs via the fecal-oral route or via contact with skin lesions and oral secretions. Viremia develops, followed by invasion of the skin and mucous membranes. Widespread apoptosis likely results in the characteristic lesion formation.

Frequency

United States

Epidemics of HFMD generally occur in the summer to early fall months, although cases can occur sporadically all year.

International

HFMD epidemics associated with EV-71 have been more frequent in Southeast Asia in recent years, including Taiwan (1998) and Singapore (2000). Risk factors in these epidemics include attendance at child care centers, contact with HFMD, large family number, and rural residence.[7]

Mortality/Morbidity

HFMD caused by coxsackievirus is generally a mild self-limited illness that resolves in 7-10 days; rarely, HFMD may recur or persist. Serious complications are also rare.

Severe oral ulcerations can create painful stomatitis. This may interfere with oral intake and cause dehydration, the most common complication of HFMD. Rarely, aseptic meningitis accompanies coxsackievirus-induced HFMD.

HFMD caused by EV-71 has a higher incidence of neurologic involvement, including a poliolike syndrome, aseptic meningitis, encephalitis, encephalomyelitis, acute cerebellar ataxia, acute transverse myelitis, Guillain-Barré syndrome, opsomyoclonus syndrome, and benign intracranial hypertension. These neurological complications have been attributed to either immunopathology or virus-induced damage to gray matter.[1, 8]

Rarely, cardiopulmonary complications such as myocarditis, interstitial pneumonitis, and pulmonary edema may occur. Neurologic involvement with sequelae is less likely to occur in patients with HFMD caused by coxsackievirus strains than with HFMD caused by EV-71. Chang et al analyzed the Taiwan HFMD epidemic of 1998 and revealed that 68% of the EV-71 cases were uncomplicated.[9] Thirty-two percent of the cases had complications; 7.3% involved aseptic meningitis, 10% involved encephalitis, 2.3% involved poliolike syndrome, 4.5% involved encephalomyelitis, and 6.8% involved fatal pulmonary edema (7.9% of patients died and 4% of patients had sequelae). In the coxsackievirus A16 group, 94% of the cases of were uncomplicated; only 6.3% cases were complicated by aseptic meningitis; no fatalities or sequelae were reported.

Chong et al observed vomiting, leukocytosis, and an absence of mouth ulcers as predictive risk factors for fatal cases of EV-71 HFMD during the Singapore epidemic in 2000.[2]

Sex

Most reports indicate that HFMD has no sexual predilection. Some epidemic data observe a slight male-to-female predominance ratio of 1.2-1.3:1.

Age

Children younger than 10 years are most commonly affected with HFMD, and subsequent outbreaks among family members and close contacts may develop.[10]

History

The incubation period of hand-foot-and-mouth disease (HFMD) lasts approximately 1 week; patients then report a sore mouth or throat. Malaise may develop. Rarely, vomiting occurs in HFMD cases caused by EV-71.

Physical

Initially, macular lesions appear on the buccal mucosa, tongue, and/or hard palate. These mucosal lesions rapidly progress to vesicles that erode and become surrounded by an erythematous halo, as shown in the image below. Skin lesions, which present as tender macules or vesicles on an erythematous base, develop in approximately 75% of patients with HFMD. A fever of 38-39°C may be present for 24-48 hours.



View Image

The lower lip has an ulcer with an erythematous halo.

Atypical clinical features may be present. HFMD caused by coxsackievirus strains rarely presents with concomitant aseptic meningitis.[1] HFMD caused by EV-71 has a higher incidence of neurologic involvement, including a poliolike syndrome, aseptic meningitis, encephalitis, encephalomyelitis, acute cerebellar ataxia, acute transverse myelitis, Guillain-Barré syndrome, opsomyoclonus syndrome, and benign intracranial hypertension.[2]

Causes

HFMD is most commonly caused by coxsackievirus A16, but it is also caused by coxsackieviruses A5, A7, A9 A10, B2, and B5 and EV-71. Two major genotypes of EV-71, EV-71 B and C, have been identified as the strains principally involved in the EV-71 HFMD epidemics in Australia, Malaysia, Singapore, Taiwan, and Japan since 1997. These genotypes are considered particularly neurovirulent, accounting for the severe neurologic complications seen in EV-71 HFMD epidemics.[11]

Laboratory Studies

The diagnosis of hand-foot-and-mouth disease (HFMD) is typically based on clinical grounds. Laboratory studies are usually unnecessary.

The virus can be isolated and identified via culture and immunoassay from cutaneous lesions, mucosal lesions, or stool samples. Oral specimens have the highest isolation rate. In patients with vesicles, vesicle swabs are also a good source for viral collection. In patients without vesicles, rectal swabs can be collected. For viral isolation, 2 swab collections are recommended—from the throat and the other from either vesicles or the rectum.

Serologic testing (eg, acute and convalescent antibody levels) may be obtained.

Differentiating coxsackie-associated from EV-71–associated HFMD may have prognostic significance. Polymerase chain reaction (PCR) and microarray technology are among the various ways of identifying the causative virus. Specific assays vary between hospitals.[3]

Medical Care

The treatment of hand-foot-and-mouth disease (HFMD) is supportive. In fact, there is no antiviral agent specific for the etiologic agents. Ensure adequate fluid intake to prevent dehydration. Cold liquids are generally preferable. Spicy or acidic substances may cause discomfort. Intravenous hydration may be necessary if the patient has moderate-to-severe dehydration or if discomfort precludes oral intake. Fever may be treated with antipyretics. Pain may be treated with standard doses of acetaminophen or ibuprofen. Direct analgesia may also be applied to the oral cavity via mouthwashes or sprays. Intravenous immunoglobulin (IVIG) and milrinone have shown some efficacy in a few reports.[4, 5, 6]

There is a relative dearth of treatment options for enterovirus-associated HFMD cases. Recent research has yielded several promising novel and existing therapeutics targeting specific viral mechanisms of action. These include molecular decoys, receptor antagonists, uncoating and translation inhibitors, polyprotein processing inhibitors, and replication inhibitors. Pleconaril is an uncoating inhibitor that shows promise in enterovirus 71–associated infections.

Amantadine and quinacrine, both translation inhibitors, and ribavirin, a replication inhibitor, are also being investigated as treatment options.[12]

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Acetaminophen (Tylenol, Aspirin Free Anacin, Feverall)

Clinical Context:  Reduces fever by acting directly on hypothalamic heat-regulating centers, which increases dissipation of body heat via vasodilation and sweating.

Ibuprofen (Motrin, Ibuprin)

Clinical Context:  One of the few NSAIDs indicated for reduction of fever.

Class Summary

These agents are used to control fever and pain.

Lidocaine anesthetic (Dermaflex)

Clinical Context:  Decreases permeability to sodium ions in neuronal membranes. This results in the inhibition of depolarization, blocking the transmission of nerve impulses.

Class Summary

These agents can be applied to ulcerations to control pain.

Diphenhydramine hydrochloride (Benadryl, Benylin)

Clinical Context:  For symptomatic relief of symptoms caused by release of histamine in allergic reactions.

Class Summary

These agents act by competitive inhibition of histamine at the H1 receptor.

Further Outpatient Care

Closely observe infants with HFMD for development of dehydration.

Clinical improvement is observed after approximately 3-5 days; cutaneous and mucosal lesions resolve in 7-10 days. The patient may continue to shed virus through the stool for weeks.

Further Inpatient Care

Patients with CNS manifestations of hand-foot-and-mouth disease (HFMD; eg, encephalitis, aseptic meningitis) may require hospitalization.

Complications

Rarely, aseptic meningitis and other neurological complications accompany HFMD. More commonly, oral ulcerations can interfere with fluid intake and cause dehydration, the most common complication of HFMD.

Rare case reports show spontaneous abortions associated with HFMD.

Prognosis

The prognosis of HFMD is excellent. The vast majority of patients with this infection are expected to recover fully.

What is hand-foot-and-mouth disease (HFMD)?What are the signs and symptoms of hand-foot-and-mouth disease (HFMD)?Which neurological conditions are associated with hand-foot-and-mouth disease (HFMD)?How is hand-foot-and-mouth disease (HFMD) diagnosed?How is hand-foot-and-mouth disease (HFMD) managed?What is hand-foot-and-mouth disease (HFMD)?What is coxsackievirus?What is the pathogenesis of hand-foot-and-mouth disease (HFMD)?At what time of the year are hand-foot-and-mouth disease (HFMD) epidemics most likely to occur?What are the risk factors for developing hand-foot-and-mouth disease (HFMD)?How long does hand-foot-and-mouth disease (HFMD) normally last?What are common complications of hand-foot-and-mouth disease (HFMD)?Which etiologic factor increases the risk of neurological involvement in hand-foot-and-mouth disease (HFMD)?Which complications are more likely to occur with hand-foot-and-mouth disease (HFMD) caused by enterovirus 71 (EV-71)?Is hand-foot-and-mouth disease (HFMD) more common in males or females?Which age groups are most affected by hand-foot-and-mouth disease (HFMD)?What is the incubation period for hand-foot-and-mouth disease (HFMD)?Which physical findings suggest hand-foot-and-mouth disease (HFMD)?What are atypical physical findings of hand-foot-and-mouth disease (HFMD)?Which viruses cause hand-foot-and-mouth disease (HFMD)?Which disorders should be included in the differential diagnoses of hand-foot-and-mouth disease (HFMD)?What are the differential diagnoses for Hand-Foot-and-Mouth Disease (HFMD)?How is hand-foot-and-mouth disease (HFMD) diagnosed?What is the treatment for hand-foot-and-mouth disease (HFMD)?Are there any treatment options for enterovirus-associated hand-foot-and-mouth disease (HFMD)?What is the goal of pharmacotherapy for hand-foot-and-mouth disease (HFMD)?Which medications in the drug class Antipyretics/analgesics are used in the treatment of Hand-Foot-and-Mouth Disease (HFMD)?Which medications in the drug class Topical anesthetics are used in the treatment of Hand-Foot-and-Mouth Disease (HFMD)?Which medications in the drug class Antihistamines are used in the treatment of Hand-Foot-and-Mouth Disease (HFMD)?What is the standard outpatient care for hand-foot-and-mouth disease (HFMD)?When is hospitalization indicated in the treatment of hand-foot-and-mouth disease (HFMD)?What are possible complications of hand-foot-and-mouth disease (HFMD)?What is the prognosis of hand-foot-and-mouth disease (HFMD)?

Author

Stephen J Nervi, MD, Staff Physician, Department of Dermatology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Disclosure: Nothing to disclose.

Coauthor(s)

Rajendra Kapila, MD, MBBS, Professor, Department of Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Thomas M Kerkering, MD, Chief of Infectious Diseases, Virginia Tech Carilion School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Disclosure: Nothing to disclose.

Additional Contributors

Gary L Gorby, MD, Associate Professor, Departments of Internal Medicine and Medical Microbiology and Immunology, Division of Infectious Diseases, Creighton University School of Medicine; Associate Professor of Medicine, University of Nebraska Medical Center; Associate Chair, Omaha Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

Acknowledgements

Diane H Johnson, MD Assistant Director, Assistant Professor, Department of Internal Medicine, Division of Infectious Diseases, Winthrop-University Hospital, State University of New York at Stony Brook School of Medicine

Diane H Johnson, MD is a member of the following medical societies: American College of Physicians, American Medical Association, American Medical Women's Association, American Society for Microbiology, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

References

  1. Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003 Jan. 9(1):78-85. [View Abstract]
  2. Chong CY, Chan KP, Shah VA, Ng WY, Lau G, Teo TE, et al. Hand, foot and mouth disease in Singapore: a comparison of fatal and non-fatal cases. Acta Paediatr. 2003 Oct. 92(10):1163-9. [View Abstract]
  3. Chen TC, Chen GW, Hsiung CA, Yang JY, Shih SR, Lai YK, et al. Combining multiplex reverse transcription-PCR and a diagnostic microarray to detect and differentiate enterovirus 71 and coxsackievirus A16. J Clin Microbiol. 2006 Jun. 44(6):2212-9. [View Abstract]
  4. Thomas I, Janniger CK. Hand, foot, and mouth disease. Cutis. 1993 Nov. 52(5):265-6. [View Abstract]
  5. Toida M, Watanabe F, Goto K, Shibata T. Usefulness of low-level laser for control of painful stomatitis in patients with hand-foot-and-mouth disease. J Clin Laser Med Surg. 2003 Dec. 21(6):363-7. [View Abstract]
  6. Wang SM, Liu CC. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther. 2009 Aug. 7(6):735-42. [View Abstract]
  7. Saeed A, Khan QM, Waheed U, Arshad M, Asif M, Farooq M. RT-PCR evaluation for identification and sequence analysis of foot-and-mouth disease serotype O from 2006 to 2007 in Punjab, Pakistan. Comp Immunol Microbiol Infect Dis. 2011 Mar. 34(2):95-101. [View Abstract]
  8. Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT. An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg. 2007 Jul. 77(1):188-91. [View Abstract]
  9. Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J. 1999 Dec. 18(12):1092-6. [View Abstract]
  10. Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics. 2007 Aug. 120(2):e244-52. [View Abstract]
  11. Ahmad K. Hand, foot, and mouth disease outbreak reported in Singapore. Lancet. 2000 Oct 14. 356(9238):1338. [View Abstract]
  12. Tan CW, Lai JK, Sam IC, Chan YF. Recent developments in antiviral agents against enterovirus 71 infection. J Biomed Sci. 2014. 21:14. [View Abstract]
  13. Boughton B. EV71: Vaccine Prevents Hand-Foot-Mouth, Associated Disease. Medscape Medical News. Available at http://www.medscape.com/viewarticle/804983. Accessed: June 4, 2013.
  14. Chan YF, AbuBaker S. Recombinant human enterovirus 71 in hand, foot and mouth disease patients. Emerg Infect Dis. 2004 Aug. 10(8):1468-70. [View Abstract]
  15. Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002 Jun. 109(6):e88. [View Abstract]
  16. Cherry JD. Contemporary infectious exanthems. Clin Infect Dis. 1993 Feb. 16(2):199-205. [View Abstract]
  17. Faulkner CF, Godbolt AM, DeAmbrosis B, Triscott J. Hand, foot and mouth disease in an immunocompromised adult treated with aciclovir. Australas J Dermatol. 2003 Aug. 44(3):203-6. [View Abstract]
  18. Frydenberg A, Starr M. Hand, foot and mouth disease. Aust Fam Physician. 2003 Aug. 32(8):594-5. [View Abstract]
  19. Hooi PS, Chua BH, Lee CS, Lam SK, Chua KB. Hand, foot and mouth disease: University Malaya Medical Centre experience. Med J Malaysia. 2002 Mar. 57(1):88-91. [View Abstract]
  20. Kuo RL, Kung SH, Hsu YY, Liu WT. Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. J Gen Virol. 2002 Jun. 83(Pt 6):1367-76. [View Abstract]
  21. McMinn P, Stratov I, Nagarajan L, Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis. 2001 Jan 15. 32(2):236-42. [View Abstract]
  22. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002 Mar. 26(1):91-107. [View Abstract]
  23. Miller GD, Tindall JP. Hand-foot-and-mouth disease. JAMA. 1968 Mar 4. 203(10):827-30. [View Abstract]
  24. Modlin JF. Enterovirus deja vu. N Engl J Med. 2007 Mar 22. 356(12):1204-5. [View Abstract]
  25. Modlin JF. Coxsachie Virus, Echoviruses, and Newer Enteroviruses. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease. 5th ed. 2000. 1904-17.
  26. Ooi MH, Solomon T, Podin Y, Mohan A, Akin W, Yusuf MA, et al. Evaluation of different clinical sample types in diagnosis of human enterovirus 71-associated hand-foot-and-mouth disease. J Clin Microbiol. 2007 Jun. 45(6):1858-66. [View Abstract]
  27. Ooi MH, Wong SC, Clear D, Perera D, Krishnan S, Preston T, et al. Adenovirus type 21-associated acute flaccid paralysis during an outbreak of hand-foot-and-mouth disease in Sarawak, Malaysia. Clin Infect Dis. 2003 Mar 1. 36(5):550-9. [View Abstract]
  28. Prager P, Nolan M, Andrews IP, Williams GD. Neurogenic pulmonary edema in enterovirus 71 encephalitis is not uniformly fatal but causes severe morbidity in survivors. Pediatr Crit Care Med. 2003 Jul. 4(3):377-81. [View Abstract]
  29. Scott LA, Stone MS. Viral exanthems. Dermatol Online J. 2003 Aug. 9(3):4. [View Abstract]
  30. Shekhar K, Lye MS, Norlijah O, Ong F, Looi LM, Khuzaiah R, et al. Deaths in children during an outbreak of hand, foot and mouth disease in Peninsular Malaysia--clinical and pathological characteristics. Med J Malaysia. 2005 Aug. 60(3):297-304. [View Abstract]
  31. Shimizu H, Okuyama K, Hirai Y. Epidemic of hand, foot and mouth disease in Kawasaki City, Japan. Jpn J Infect Dis. 2005 Oct. 58(5):330-1. [View Abstract]
  32. Shimizu H, Utama A, Onnimala N, Li C, Li-Bi Z, Yu-Jie M, et al. Molecular epidemiology of enterovirus 71 infection in the Western Pacific Region. Pediatr Int. 2004 Apr. 46(2):231-5. [View Abstract]
  33. Singh S, Poh CL, Chow VT. Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore (2000). Microbiol Immunol. 2002. 46(11):801-8. [View Abstract]
  34. Solomon T. Exotic and emerging viral encephalitides. Curr Opin Neurol. 2003 Jun. 16(3):411-8. [View Abstract]
  35. Sutton-Hayes S, Weisse ME, Wilson NW, Ogershok PR. A recurrent presentation of hand, foot, and mouth disease. Clin Pediatr (Phila). 2006 May. 45(4):373-6. [View Abstract]
  36. Tsao KC, Chang PY, Ning HC, Sun CF, Lin TY, Chang LY, et al. Use of molecular assay in diagnosis of hand, foot and mouth disease caused by enterovirus 71 or coxsackievirus A 16. J Virol Methods. 2002 Apr. 102(1-2):9-14. [View Abstract]
  37. Tsao LY, Lin CY, Yu YY, Wang BT. Microchip, reverse transcription-polymerase chain reaction and culture methods to detect enterovirus infection in pediatric patients. Pediatr Int. 2006 Feb. 48(1):5-10. [View Abstract]
  38. Tseng FC, Huang HC, Chi CY, Lin TL, Liu CC, Jian JW, et al. Epidemiological survey of enterovirus infections occurring in Taiwan between 2000 and 2005: Analysis of sentinel physician surveillance data. J Med Virol. 2007 Dec. 79(12):1850-60. [View Abstract]
  39. Wang CY, Li Lu F, Wu MH, Lee CY, Huang LM. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J. 2004 Mar. 23(3):275-6. [View Abstract]
  40. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013 May 28. [View Abstract]
  41. Zhu Z, Xu WB, Xu AQ, Wang HY, Zhang Y, Song LZ, et al. Molecular epidemiological analysis of echovirus 19 isolated from an outbreak associated with hand, foot, and mouth disease (HFMD) in Shandong Province of China. Biomed Environ Sci. 2007 Aug. 20(4):321-8. [View Abstract]

The lower lip has an ulcer with an erythematous halo.

The lower lip has an ulcer with an erythematous halo.

The lower lip has an ulcer with an erythematous halo.

Illness Etiologic Agent Usual Severity of Clinical Illness Appearance of Lesions Locations of Lesions Other Features
HFMDCoxsackie-virus A16 (most common), A5, A7, A9, A10, B2, B5



Enterovirus 71



MildPapules →



Vesicles → ulcerations on an erythematous base



Usually 2-6 mm



Gingiva



Buccal mucosa



Tongue



Pharynx



Lesions may also be found on hands, feet, buttocks, and genitalia.



Low-grade fever



HerpanginaCoxsackie-virus A1-A10, A16, A22



Echovirus 3, 6, 9, 16, 17, 25, 30



Moderate; can be severePapules →



Vesicles → ulcerations on an erythematous base



Usually 2-4 mm



Posterior oral cavity



Tonsils, soft palate, uvula



Temperature generally high
Herpetic gingivostomatitisHerpes simplex virus-1Moderate to severeVesicles



ulcerations



Anterior oral cavity



Lips, gingiva, buccal mucosa



Temperature generally high



Lymphadenopathy



Aphthous stomatitisUnknownMild to severeUlcerations; larger than in viral enanthemsLips, tongue, buccal mucosa; generally not diffuseAfebrile



May be recurrent



Stevens-Johnson syndromeImmunologicModerate to severeCoalescent vesicles, which then ulcerateLips, gingiva, buccal mucosa, tongue, pharynxTargetlike cutaneous lesions



Diffuse mucous membrane involvement